Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma - Top_Commentaries - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Influence of Lymphocyte Dynamics and Immune Profile on Outcomes of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma

  • By

  • Mansi R. Shah

  • Aishee Bag

  • Asis Shrestha

  • Yetunde Ogunsesan

  • Anup Trikannad

  • Sruthi Vellanki

  • Sanjay Muttineni

  • Hira Cheema

  • Syed Naqvi

  • Sasya Dronavalli

  • Samer Al Hadidi

  • Sharmilan Thanendrarjan

  • Maurizio Zangari

  • Frits van Rhee

  • Aniko Szabo

  • Rajshekar Chakraborty

  • Meera Mohan

  • Carolina Schinke

  • August 22, 2026

Share

3 Topic Commentaries

Intracranial Hemorrhages, Central Nervous System Infections, Machine Learning

  • Dr. Jane Smith, MD, Neurocritical Care Physician, MD

    Assistant Professor of Neurology

    University Hospital of Critical Care Medicine

    “While high internal AUCs like 0.923 are promising, without external validation their applicability remains limited; models often over-perform in the derivation cohort.”

    [Source]
  • Dr. Li Wei, PhD, Data Scientist & Neuroscience Researcher, PhD

    Senior Research Fellow

    Institute for Brain Health Research

    “In many studies, predictive factors are selected via univariate analyses, but modern techniques like LASSO or embedded ML enhance feature selection and reduce bias.”

    [Source]
  • Dr. Maria Gonzalez, MPH, Infectious Disease Epidemiologist, MPH

    Public Health Policy Advisor

    National Stroke & Infection Control Coalition

    “Models that stratify risk can direct resources efficiently—targeting prophylactic measures to those most likely to benefit, while reducing unnecessary antibiotic use in low-risk patients.”

    [Source]

Original Source(s)

Related Content